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Poly(ethylene glycol) (PEG)ylation of peptides and proteins creates significant challenges for
detailed structural characterization, such as PEG heterogeneity, site of addition and number of
attached PEGylated moieties. Recently, we published a novel LC/MS methodology with a
post-column addition of amines to obtain accurate masses of PEGylated peptides and proteins.
The accurate masses can be used to assign the structures and number of attached PEGs [15],
but the PEGylation site remains unclear in situations where multiple potential attachments are
involved. Here, we present a methodology combining in-source fragmentation (ISF) with
CID-MS/MS to elucidate the PEGylated sites in PEGylated products. All PEGylated samples,
either prepared in acidic solution, or collected from a RP-HPLC stream, were first ionized via
ISF to produce products containing small PEG fragment attachment, and then those fragment
ions obtained were sequenced via CID MS/MS to deduce the PEGylation site. The method-
ology was successfully applied to PEGylated glucagon and IgG4 antibody light chain, which
demonstrated that the small PEG fragments attached were stable during the CID
activation. (J Am Soc Mass Spectrom 2010, 21, 810–818) © 2010 American Society for
Mass SpectrometryProteins and peptides have experienced tremen-dous growth in the pharmaceutical industry aspotential therapeutics since the inception of re-
combinant DNA technologies and advances in solid-
phase synthetic methods [1, 2]. Despite these advances
in production capability, the inherent chemical and
physical instability of peptides and proteins as well as
their susceptibility to proteolytic degradation and rapid
clearance in vivo complicates formulation development
and limits delivery to daily injections. Because injec-
tions are considered inconvenient and may impact
patient compliance, one approach has focused on in-
creasing the short circulating half-life of peptides and
proteins in vivo (pharmacokinetics) by means of molec-
ular modifications. Common molecular modification
strategies include: increasing the sialic acid content of
glycan residues [3], covalent conjugation with albumin
[4, 5], or the Fc region of IgG [6], and most successfully,
attachment of water-soluble poly(ethylene glycol) (PEG)
moieties [7].
Following the pioneering research of Davis [7–8] and
Abuchowsky [7] in late 1970s, PEGylation of peptides
and proteins has quickly become a widely used drug
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immunogenic, and amphiphilic PEG moieties should
not impair the efficacy of biopharmaceuticals but sig-
nificantly improve the pharmacokinetic behavior by
increasing solubility, reducing immunogenicity, im-
proving stability, and extending circulation half-life in
vivo [9–11]. Since the first PEGylated biopharmaceuti-
cal, ‘Adagen’, was approved by the FDA in 1990, there
have been at least eight PEGylated proteins approved
and marketed, and still more in clinical trials, which
target a broad range of diseases including cancer,
hepatitis, gout, and diabetes [11]. Despite the growing
interest, PEGylation of peptides and proteins still cre-
ates significant challenges for detailed structural char-
acterization, such as the PEG polydispersity, site of
addition, and number of attached PEGs.
When conventional ESI-MS was used for detection,
PEGylated products were normally heavily charged,
leading to overlap of different charge ions in the final
mass spectra and often the fragmentation of the PEG
chains. As a result of these issues, most previously
reported studies relied on MALDI-MS due to its typical
singly-charged ionization [12–14]. Nevertheless, the appli-
cation of MALDI to large molecular weight PEGylated
products often yielded limited structural information
due to the technique’s limited resolution in the linear
mode. Recently, we published a novel LC/ESI-MS
methodology with a post-column addition of amines to
obtain accurate masses of PEGylated peptides and
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assign some structural elements (e.g., dimerization,
oxidation, maleimide ring opening by hydrolysis, etc.)
and number of attached PEGs, the site of PEG addition
still remained unknown in situations where multiple
potential sites existed.
Depending on the proximity to the binding region,
PEGylated sites might have an influence on the biolog-
ical activity of the conjugated molecules. Furthermore,
the presence of multiple potential PEGylation sites
could easily lead to a mixture of positional isomers, so
the identification of those sites is very crucial for the
characterization of PEGylated drugs, and provides
important information needed to support regulatory
submissions. To date, many techniques have been com-
bined to address the problem of locating PEG attach-
ment sites [16–25]. Edman degradation, the most
widely used method for short peptides, was applied to
determine the PEGylation site based on the absence of
expected amino acids in the sequence [19]. Since large
peptides and proteins often require prior enzyme cleav-
age to generate smaller fragments, the application of
Edman degradation has to overcome the difficulties in
isolating and purifying the individual fragments after
digestion. Some studies, based on enzymatic diges-
tion followed by peptide mapping, reported that the
PEGylation sites could be located by comparing the
peptide maps of PEGylated and native proteins [20],
but the PEGylation itself might also affect the protease
digestion and, therefore, complicate the final data inter-
pretation. All of the cited studies focused on samples
modified with relatively small size PEGs. Recently, a
novel MALDI-TOF methodology using reflector in-
source decay successfully identified the PEGylation site
of 20 kDa PEGylated peptides because the attachment
of the large PEG truncated the fragment ion series at the
PEGylation site (residue) [18]. However, this method is
not applicable when multiple potential sites exist. An-
other conventional method involves dePEGylation,
which removes PEG moieties from the protein molecule
and minimizes the difficulties of PEGylation site map-
ping. For example, BrCN treatment of two novel PEG
derivatives, PEG-Met-Nle-OSu and PEG-Met-Ala-
OSu, removed PEG leaving Nle or Ala at the origi-
nal PEGylated sites [21]. NMR is another power-
ful tool that has been applied for PEGylation site
mapping [24, 25], but the general limitation associ-
ated with analysis of large molecular weight samples
still must be considered. Taken together, current
PEGylation site mapping procedures are either
based on indirect observations, or only limited to
specific PEGylated molecules. Here we report a novel
PEGylation site mapping procedure that is based on
direct observation from conventional CID MS/MS for
peptide ions with small PEG fragment attached,
which was obtained during electrospray ionization
with in-source fragmentation.Experimental
Materials
Intact glucagon, 5 kDa PEGylated glucagon, glucagon,
and IgG4 antibody were produced at Eli Lilly and
Company (Indianapolis, IN, USA); 20 kDa methoxyl
poly(ethylene glycol) para-nitrophenylcarbonate (mPEG-
PNP) was purchased from Dow Chemical (Midland,
MI, USA); 20 kDa methoxyl poly(ethylene glycol), ma-
leimide (mPEG-MAL) was purchased from NOF Cor-
poration (Tokyo, Japan). All standard buffer solutions
were purchased from Fisher Scientific (Pittsburgh, PA,
USA). Diethylmethylamine (DEMA) was purchased
from Aldrich (St. Louis, MO, USA). Endoproteinase
Lys-C was purchased from Wako Chemical USA, Inc.
(Richmond, VA, USA). Dithiothreitol (DTT) and 8.0 M
Guanidine HCl were purchased from Pierce Biotechnol-
ogy (Rockford, IL, USA). All other chemicals were
reagent grade and commercially available.
Sample Preparation
To demonstrate the application of the methodology,
two model PEGylated products, PEGylated glucagon
and partially reduced IgG light chain were used. A
variety of PEGylation chemistries is available to attach
poly(ethylene glycol) (PEG) to peptide or protein
(PEGylation) [26], and two approaches were employed
in this work. A 5 or 20 kDa PEGylated glucagon sample
was made by reacting glucagon with 5 or 20 kDa
methoxyl poly(ethylene glycol) para-nitrophenylcar-
bonate (mPEG-PNP), which reacts with amine groups
of Lys and His or the N-terminus. Glucagon has two
potential reaction sites, His1 and Lys12. A 20 kDa
PEGylated IgG4 light chain sample was synthesized
through maleimide chemistry using 20 kDa methoxyl
poly(ethylene glycol) maleimide (mPEG-MAL) reaction
with sulfhydryl group of Cys residue of partially re-
duced IgG4 light chain. Partially reduced IgG4 light
chain only contains one reduced Cys residue.
The 20 kDa PEGylated glucagon and 20 kDa
PEGylated IgG4 antibody samples were prepared as
previously described [15]. A solution of 5 kDa
PEGylated glucagon was freshly prepared at a concen-
tration of 0.5 mg/mL in 0.05% TFA before MS analysis.
To produce positional isomers having alternate sites
of PEGylation, different pH buffer solutions were
employed to adjust the synthetic conditions for
PEGylation. To locate the conjugation site of PEGylated
IgG4 before the Lys-C digestion, PEGylated IgG4 anti-
body was subjected to full reduction and alkylation
using DTT and iodoacetamide, respectively. Briefly, 200
L of PEGylated IgG4 solution (100 g antibody) was
lyophilized and resuspended in 10 L of 250 mM Tris
buffer, pH 8, containing 6 M guanidine · HCl. After the
sample was fully dissolved, the solution was mixed
with 2 L of 500 mM DTT with subsequent incubation
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was alkylated by adding 5 L of 50 mg/mL iodoacet-
amide and then diluted to 100 L with 50 mM Tris
buffer, pH 8.0. The final sample was mixed with Lys-C
in a 1:50 enzyme-to-antibody ratio (weight/weight) and
incubated at 37 °C for 3 h.
Reversed-Phase HPLC Chromatography
AWaters Alliance HPLC system model 2795 or Acquity
UPLC (Waters, Milford, MA, USA) was used for all the
separations. For all analyses, the HPLC column was a
Polymer Lab polymer C18 (2.1  50 mm, 8 m particle
size, 1000 Å pore size) (Amberst, MA, USA). The flow
rate was 200 L/min, and the column was maintained
at 60 °C. The solvents were: (A) 0.05% aqueous trifluoro
acetic acid (TFA) solution, and (B) 0.04% TFA in aceto-
nitrile. For intact PEGylated glucagon, partially reduced
IgG4 or Lys-C digest analysis, the column was equili-
brated with 20% B before sample injection. After the
injection of sample, a gradient elution was performed
from 20% to 40% B in 8 min, to 52% (46% for UPLC) B
over 2 min, to 56% B (49% for UPLC) over 14 min, then
to 90% B over 1 min, and held at 90% B for 1.5 min, and
then rapidly returned to initial conditions. Post-column
addition was performed with a steady flow rate of 60
L/min of amine solution (0.05% amine in 50% aceto-
nitrile solution) introduced by HPLC pump.
MS Analysis
A Waters Alliance HPLC or Acquity UPLC system
model 2795 was coupled to a Waters LCT Premier or a
Waters SYNAPT HDMS mass spectrometer (Waters
Corp.). The HPLC effluent was introduced directly into
the mass spectrometer without splitting the stream. The
samples were first characterized using LC-MS with a
post-column addition of DEMA as previously described
[15]. MS was performed with the following settings:
capillary voltage of 3.2 kV, cone voltage of 150 V,
Aperture 1 of 100 V, mass range of 400 to 15,990,
desolvation temperature of 300 °C, and desolvation gas
flow at 700 L/h. Deconvolution of collected mass spec-
tra was carried out using MassLynx (ver. 4.1) MaxEnt 1
software (Waters Corp.). To induce ISF of PEGylated
products, the same LC-MS method was performed
without the post-column addition of DEMA, and either
aperture 1 (LCT Premier) or cone voltage (SYNAPT) of
mass spectrometer was elevated to obtain protein or
peptide attached with small PEG fragments. MS was
performed with the following settings: capillary voltage
of 3.2 kV, cone voltage of 150 or 60 V (for SYNAPT),
Aperture 1 of 60 or 0 V (for SYNAPT), mass range of
400–15,990 or 50–2000 or 3000 (for SYNAPT), desolva-
tion temperature of 300 °C, and desolvation gas flow at
700 L/h. CID MS/MS measurements were performed
using a Waters SYNAPT HDMS mass spectrometer,
where fragment ions of the peptides attached withsmall PEG fragments were selectively activated by CID
(collision energy of 50.0 or 25 eV for PEGylated glu-
cogan or Lys-C peptide of IgG4 light chain, respec-
tively) and then analyzed in the TOF analyzer. The
MS/MS spectrum for 5 kDa PEGylated glucagon was
obtained with the direct infusion at 10 L/min.
Results and Discussion
DePEGylation is an efficient approach to simplify the
PEGylated products and enable determination of
the PEGylation site. However, previous established
dePEGylation procedures are only applicable for cer-
tain PEG linkages, and often require specific reagents.
As mentioned, the application of conventional ESI-MS
for PEGylation characterization normally leads to the
fragmentation of PEG chains, a process that is similar to
dePEGylation but can be generally employed for a
variety of PEGylated products. Here, we utilized
charge-induced fragmentation to facilitate the identifi-
cation of PEGylation site.
Five kDa PEGylated Glucagon
Five kDa PEGylated glucagon, whose PEGylation site
had been mapped to the residue Lys12 by previous
electron transfer dissociation (ETD) experiments [27],
was first selected as a model system for our studies. As
shown in Figure 1a, with a post-column addition of
DEMA, deconvoluted mass spectra clearly revealed the
polydispersity of amine-adducted molecules. It should
be noted that the deconvoluted MS spectrum does not
have an expected Gaussian distribution for the
PEGylated glucagon sample. The cause of this profile is
likely related to the manner in which the sample was
purified. The mass spectral (molecular weight) profile
of PEG or PEGylated product should have a normal
(Gaussian) distribution. However, the 5 kD PEGylated
glucagon sample we used did not show a normal
distribution, and the high mass region was truncated
(see Figure 1). This is because the 5 kDa PEGylated
glucagon used in our study was a purified product by
RP-HPLC after the PEGylation. To obtain purer
PEGylated glucagon, the late eluting region of the
PEGylated glucagon peak was cut during the peak
collection. To induce the ISF, we removed the post-
column addition of DEMA, and treated the 5 kDa
PEGylated glucagon sample with harsh mass spectro-
metric conditions (i.e., high aperture 1 or sample cone
voltages). As shown in Figure 1b, a series of triply
charged ions were observed in the 1300–2000 (m/z)
range with a 14.7 spacing between each adjacent ion
peak. Since short PEG fragmentation ions are normally
singly charged based on the same analysis for PEG itself
[15], these ions should represent a series of PEGylated
glucagon with a mass range of 3900–6000 Da. Because
the molecular weight of each oxyethylene unit is 44 Da,
the number of oxyethylene units can be easily calcu-
lated by the accurate mass for each ion. For example,
is is m
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strongest isotopic ion and the monoisotopic ion is
1396.0) is highly consistent with the expected mass of
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814 LU ET AL. J Am Soc Mass Spectrom 2010, 21, 810–818To localize the PEGylation site, the ion at m/z 1396.7
was selected as the precursor ion to perform conven-
tional CID MS/MS. As shown in Figure 2, all b ions that
are smaller than the b11 ion were found unmodified, but
the singly charged b15 ion shifted from 1730.8 to 2435.3,
and the doubly charged b21 ion also shifted from 1222.6
to 1574.8. The mass shifts from both b ions are equal and
match exactly the short PEG attachment containing 15
oxyethylene units. Similarly, all y ions containing resi-
due Lys12 are also found to be PEGylated with 15
oxyethylene units, while those without the attachment
have the expected calculated mass, indicating no PEG
attachment. Taken together, the combination of ISF and
CID MS/MS allowed us to directly determine that
glucagon was PEGylated at Lys12, which was consis-
tent with previous results. Nevertheless, compared
with previous studies that relied on the high-end ETD
instrumentation, our methodology only employed con-
ventional CID MS/MS and can be utilized in a wider
range of labs.
The data for PEGylated glucagon revealed that de-
pending on the size of PEG chain, the molecule might
have two distinct stabilities in a mass spectrometer.
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Figure 3. Deconvoluted mass spectra of 20 kDa
(b) with a post-column addition of DEMA, and m
at pH10 (c) and pH7 (d) after ISF.During ISF, the PEG chains of 5 kDa PEGylated gluca-
gon were unstable and quickly dissociated while the
peptide bonds of glucagon had been less affected.
During CID MS/MS, those low molecular weight PEG
fragments truncated by ISF were preserved while, in-
stead, the peptide bonds were dissociated. This obser-
vation might result from the different charge distribu-
tion of long and short PEG chains conjugated to a
peptide/protein. During the ionization, the PEG chains
of 5 kDa PEGylated glucagon are heavily charged. The
PEG ether bond with H ion is labile and completely
cleaved under ISF conditions. In contrast, the truncated
PEG chains obtained in the experiment do not carry any
charges (H). Thus, the attached small PEG fragment
was retained during the dissociation of polypeptide
chains.
Twenty kDa PEGylated Glucagon
It has been known that the size of PEG has to be at least
20 kDa to retard renal clearance effectively [28]. Al-
though the ETD approach can be used to directly
determine the PEGylation site of 5 kDa PEGylated
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PEGylated glucagon. Our methodology, where the
PEGylated products are initially fragmented by ISF,
should not have the same size limitation as the ETD
approach. To evaluate the capability of our methodol-
ogy, 20 kDa PEGylated glucagon was prepared by
incubating glucagon and 20 kDa mPEG-PNP together at
pH 10. Following analysis of the sample using the
post-column addition of amine method, the deconvo-
luted mass spectra revealed that the molecular weight
of DEMA-adducted mono-PEGylated glucagon has a
Gaussian distribution in the 21,000 to 26,000 Da range
(Figure 3a). As shown in Figure 3c, the ISF treatment of
these molecules led to a similar fragment ion pattern as
obtained for 5 kDa PEGylated glucagon. The following
CID MS/MS analysis of the ion at m/z 1367.3 (monoiso-
topic mass ion is 1366.7) successfully confirmed that the
20 kDa PEGylated glucagon we prepared is also
PEGylated at the Lys12 residue (see the next para-
graph). Thus, our methodology is not limited by the
size of PEG.
Glucagon contains two primary amine groups that
can react with mPEG-PNP; one at the side chain of the
Lys12 residue and the other at the N-terminus. Due to
different pKa values at these locations, only the lysine
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2 in the supplemental materials). The red and
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small PEG fragment attached is stable during CID, aamine is PEGylated at pH 10. PEGylation at the N-
terminus normally occurs at lower pH conditions. To
produce different positional isomers, the PEGylation of
glucagon was also performed at pH 9 and 7. For
comparison, the deconvoluted mass spectrum with a
post-column addition of DEMA and mass spectrum
after ISF for 20 kDa PEGylated glucagon prepared at
pH7 is shown in Figure 3b and d, respectively. They are
similar to the results (Figure 3a and c) of the 20 kDa
PEGylated glucagon prepared at pH10. As shown in
Figure 4, the decrease of the reaction pH led to a
significant change in the tandem mass spectra (the
precursor ions are always m/z 1367.3). For example, due
to the PEGylation, doubly charged y20 ions were ob-
served to be fully shifted from 1261.1 to 1569.3 for the
pH 10 produced products. When the reaction was
conducted at pH 9, the peak at 1569.3 became slightly
weaker, and a minor peak appeared at 1261.1 indicating
the presence of a small portion of unPEGylated y20 ions.
Conducting the PEGylation reaction at pH 7 produced
an increase in unPEGylated y20 ions compared to the
ions for PEGylated species. Thus, the ratio between
PEGylated and unPEGylated y20 ions became smaller as
the conjugation was carried out under lower pH condi-
tions, indicating the presence of other positional iso-
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816 LU ET AL. J Am Soc Mass Spectrom 2010, 21, 810–818mers of PEGylated glucagon. A second PEGylation site
can be easily identified as the N-terminal His residue
based on the clear observation of PEGylated a1 ions
(shift fromm/z 110.1 to 726.4) for the pH 7 products. The
other PEGylated ions, a2, b2, b3, b5, b6, and b9, were
also observed (see the supplemental tables, which can
be found in the electronic version of this article). Taken
together, these findings show that our methodology can
distinguish different PEGylation sites without any prior
separation of positional isomers.
Twenty kDa PEGylated IgG4 Antibody
Currently marketed PEGylated products are not only
composed of small proteins, but also enzymes, oligonu-
cleotides, and antibody fragments [29]. To fully evalu-
ate the capability of our methodology, PEGylated par-
tially reduced IgG4 light chain was also selected as a
model compound. To prepare this product, an IgG4
antibody was first treated with DTT under non-
denaturing conditions, which only reduced inter-chain
disulfide bonds, and produced one unpaired Cys
residue in the light chain and three in the heavy chain
[30]. The partially-reduced antibody was next incu-
bated with 20 kDa mPEG-MAL, a PEG derivative that
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Figure 5. Deconvoluted mass spectrum (a) of
addition of DEMA, mass spectrum (b) and decon
chain after ISF.selectively reacts with thiol groups of Cys residues,
successfully converting the partially reduced light
chain to a mono-PEGylated product, as shown in
Figure 5a.
Since IgG4 light chain contains a greater number
of amino acids than glucagon, the ISF treatment of
PEGylated IgG4 light chain yielded more complex mass
spectra (Figure 5b). In the 1400–2400 (m/z) range,
PEGylated IgG4 light chain fragments were distributed
in six different charge states that could be easily de-
duced to10 to15 based on the distance between two
adjacent fragment ions having the same charge. To
simplify the final data analysis, these mass spectra were
deconvoluted as shown in Figure 5c, which revealed
that ISF fragments of PEGylated light chain shared a
common structure consisting of light chain, a 208 Da
linker, and a few oxyethylene units.
Light chain has a molecular mass too large for direct
top-down PEGylation site mapping, so Lys-C digestion
was employed to reduce the size of PEGylated products
before CID MS/MS. In addition, Lys-C digestion can
concentrate the ions that distributed in the six different
charge states and increase the signal intensity of final
tandem mass spectra. Based on enzyme specificity and
accurate mass, the constant region fragment 101-107
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According to previous ISF results for PEGylated light
chain, the shortest attachment left after the fragmenta-
tion is a 208 Da linker, so the shortest PEGylated
fragment generated from the combination of Lys-C
treatment and ISF is the peptide SFNRGEC plus the
linker. Figure 6a is a mass spectrum of PEGylated Lys-C
peptides of PEGylated partially reduced IgG4 after ISF
and subtracting the background (free PEG peak). The
expected double ion (at m/z 510.7) of the peptide
SFNRGEC plus 208 Da linker is one major ion. We
selected this fragment’s doubly charged ions at 510.7
(m/z) as the precursor ions to perform CID MS/MS. As
shown in Figure 6b, all y ions were found to contain the
linker, while the b ions were intact, indicating that the
PEGylation site is in the constant region and located at
the C-terminal Cys of IgG light chain. These results
show that our methodology, combined with selective
enzyme digestion, can be successfully applied to char-
acterize PEGylated protein products with large molec-
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Figure 6. Mass spectrum (a) of PEGylated Ly
antibody obtained after ISF and subtracting the
(b) of the precursor ion at m/z 510.7 (double ion
interpretation of the product ion spectrum is su
MS/MS data assignment is provided in Table 3ular mass.Conclusions
Elucidation of PEGylation sites is a significant challenge
for the characterization of PEGylated peptide and protein
products. Here, we described an approach using the
combination of ISF and conventional CID MS/MS and
found that the small PEG fragment attachment generated
by ISF was stable during the CID activation. The experi-
ments with PEGylated glucagon and IgG4 light chain
demonstrated that the methodology is suitable for
PEGylation site mapping of various PEGylated products
without many of the complexities associated with previ-
ously described procedures. Furthermore, the application
of our methodology to a mixture of different positional
isomers successfully distinguishes the distinct PEGylation
sites without any prior separation requirement.
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